Liver dysfunction is a well-documented complication in patients with congenital heart
disease (CHD), primarily due to chronic venous congestion, reduced cardiac output, and
hypoxemia. The pathophysiology involves hepatic congestion secondary to right-sided heart
failure, leading to fibrosis and cirrhosis in advanced cases. While global studies have
extensively explored this association, regional data, particularly from Egypt, remain
limited. In this research we aim to investigate liver dysfunction in CHD patients, with a
specific focus on research conducted in Assiut, Egypt, to address gaps in localized
clinical understanding.
Hepatic complications are common in patients with CHD, resulting either from the primary
cardiac defect or from palliative surgical procedures performed in infancy or childhood
or from transfusion- or drug-related hepatitis. Given that such patients increasingly
require the expertise of a hepatologist. There are several known associations between
primary liver disease and concomitant CHD defects such as Abernethy malformation,
Alagille syndrome, and Biliary Atresia Splenic Malformation syndrome (BASM).
However, hepatic disease as a result of CHD is more common than cardiac disease
associated with liver disease. In these cases, hepatic dysfunction may ensue as a result
of the primary cardiac defect or as a result of surgical palliation, especially in
patients with single-ventricle physiology (e.g., tricuspid atresia). The mechanisms
leading to hepatic dysfunction may be multifactorial. As an example, hepatic dysfunction
may result from a combination of passive venous congestion of the liver and hypoxia, with
the latter being driven by the CHD or concomitant pulmonary disease. Volume overload and
low cardiac output may lead to both congestive hepatopathy and hepatic ischemia.
Several factors may interact to lead to end-stage liver disease. For example, patients
with underlying liver disease (e.g., viral hepatitis, alcohol, or obesity) may be more
susceptible to liver injury as a result of decreased functional mass. In addition, the
presence of cardiac disease and subsequent passive congestion may itself predispose the
liver to hepatic injury. Hypoxemia in cyanotic CHD further aggravates hepatocellular
damage, necessitating routine hepatic monitoring in this population.
Globally, the prevalence of liver dysfunction in CHD varies, with studies reporting
hepatic fibrosis in 30-40% of Fontan patients. Data from developing regions, including
Egypt, are scarce. A recent study highlighted elevated liver enzymes in CHD patients,
emphasizing the role of delayed surgical intervention in disease progression. Such
findings underscore the necessity for expanded research on hepatic complications in
Egyptian CHD cohorts.
Key risk factors for liver dysfunction in CHD include prolonged hypoxemia, high venous
pressure, and prolonged duration of heart disease. Cyanotic CHD patients exhibit higher
hepatic injury markers compared to acyanotic counterparts. In Egypt, socioeconomic
barriers often delay corrective surgeries, exacerbating hepatic damage. Early
intervention and regular hepatic surveillance are critical to improving outcomes.
Despite global advancements, Egyptian studies on CHD-related liver dysfunction are
limited. A 2016 Cairo University study identified a high prevalence of abnormal liver
function tests among CHD patients but lacked longitudinal follow-up. Further research is
needed to establish region-specific diagnostic and therapeutic protocols, considering
local healthcare challenges.
